Ida Bagus Putra Manuaba

Elevated Tumor Necrosis Factor-α and Transforming Growth Factor-β in Prostatic Tissue are Risk Factors for Lower Urinary Tract Symptoms after Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Patients with Urinary Retention

RESEARCH ARTICLE Elevated Tumor Necrosis Factor-α and Transforming Growth Factorβ in Prostatic Tissue are Risk Factors for Lower Urinary Tract Symptoms after Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Patients with Urinary Retention Gede W.K. Duarsa, Anak A. G. Oka, Sri Maliawan, Doddy M. Soebadi, Putu Astawa, Made Bakta, Dewa M. Sukrama, Ida B. P. Manuaba and Nyoman M. Astawa Urology Department, Medical Faculty of Udayana University, Sanglah Hospital Denpasar, Bali, Indonesia Medical Faculty of Udayana University, Sanglah Hospital Denpasar, Bali, Indonesia Urology Department, Medical Faculty of Airlangga University, Surabaya, Indonesia Department of Biomedical Science, Udayana University, Bali, Indonesia Department of Veterinary, Udayana University, Bali, Indonesia

INVERSE CORRELATION BETWEEN COMBINATION OF ANTIRETROVIRAL THERAPY WITH LEVEL OF SERUM INTERLEUKIN 6, FERRITIN AND HEPCIDIN IN HIV PATIENTS WITH ANEMIA OF CHRONIC DISEASE

Background: The purpose of this study was to determine whether the cARV therapy correlates with the serum level of IL-6, ferritin, and hepcidin in HIV infected patients with ACD.Methods: A cross-sectional study conducted in HIV patients with ACD, aged 15-65 years with exclusion criteria such as chronic renal disease, chronic liver disease, treated for anemia in the last 3 months, taking iron supplements in the last 3 months, history of blood transfusion in the last 1 year, suffering from acute infection, tuberculosis infection, malignancy, hepatitis C virus infection, acute hypersensitivity reaction and pregnancy. Blood specimen examined by high sensitivity human IL-6 In vitro ELISA, DRG Hepcidin- 25 ELISA, serum ferritin by agglutination method and CD4 cell count by flow cytometry. Results: A total of 86 HIV patients with ACD consist of 42 subjects with experienced cARV and 44 subjects with naive cARV. There are several differences between cARV naive and experienced cARV including: Hb (g/dl) [ 10.8 ( 9.88 – 11.75) Vs. 11.60 (11.00 – 12.34) p: 0.058 ], serum iron (mg/dl) [ 50.00 (31 – 66.8) Vs. 71.40 (56.00 – 108.00) p : 0.121 ), serum ferritin (ug/dl) [ 630 ( 194 – 1101) Vs. 195.40 (128.25 – 589.47) p: 0.008 ], IL-6 (pg/mL) [7.20 (3.88 – 10.76) Vs. 4.03 (1.69 – 8.49) p: 0.009), serum hepcidin (ng/mL) [45.54 (16.74 – 95.31) Vs. 23.35 (6.58 – 49.99) p: 0.007] , CD4 cell count (cell/uL) [31.5 (14.25 – 90.75) Vs. 307 (168.5 – 458.75) p : < 0.001)] There is a significant inverse correlation between the cARV therapy with level of serum IL-6 ( r: - 0. 285, p : 0.008), ferritin (r: - 0.321, p : 0.007) and hepcidin (r: - 0.293, p : 0.006). While there was a significant positive correlation between the cARV therapy with CD4 cell count (r: 0.676, p : 0.001). There was no correlation between the cARV therapy with serum iron levels ( r: 0.176, p : 0.121).Conclusion: There is an inverse correlation between the cARV therapy with serum level of IL-6, ferritin, and hepcidin in HIV patients with ACD. Keywords : cARV, ACD, IL-6, Ferritin, Hepcidin.